[1]CurrentPatentAssignee:ROCKCREEKADVISORSLLC-WO2018/112176,2018,A1Locationinpatent:Paragraph00394
Title: p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Journal: European journal of cancer (Oxford, England : 1990) 20160301
Title: PF-04691502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells.
Journal: Toxicology letters 20130704
Title: Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
Journal: Cancer chemotherapy and pharmacology 20120801
Title: Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
Journal: ACS medicinal chemistry letters 20111110
Title: PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Journal: Molecular cancer therapeutics 20111101
Title: Yuan J, et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther. 2011 Nov;10(11):2189-99.
